Requested symbol wasn't found

U.S. Markets open in 19 mins.


BSE - BSE Delayed Price. Currency in USD
Add to watchlist
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Avg. VolumeN/A
Market CapN/A
PE Ratio (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 years ago

    India's Sun Pharma Q2 profit up 15 pct; Cipla down on slowing exports

    Sun Pharmaceutical Industries , India's largest drugmaker by revenue, on Thursday posted a 15 percent rise in quarterly net profit, roughly in line with expectations, helped by strong growth in sales in the domestic market. Sun Pharma's smaller rival Cipla, however, reported a 16 percent drop in its quarterly profit, hit by sluggish growth in income from exports, which accounts for more than half of its revenue.

  • Reuters3 years ago

    Gilead licenses hepatitis C drug to Cipla, Ranbaxy, 5 others

    Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement. The companies will be allowed to set their own prices for the generic drug, and will pay a royalty on their earned sales to Gilead, it said.

  • Reuters3 years ago

    India's Ranbaxy gets FDA approval for Novartis's Diovan generic

    * Novartis lost patent protection on Diovan in 2012 * Ranbaxy shares up 5 pct in Mumbai, Sun Pharma up 4 pct (Adds details from company statement, background, updates share move) WASHINGTON/MUMBAI, June 27 (Reuters) - India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.